MARKET

ATHX

ATHX

Athersys Inc
OTCPK
0.027
+0.004
+14.89%
Opening 11:32 12/06 EST
OPEN
0.027
PREV CLOSE
0.024
HIGH
0.029
LOW
0.026
VOLUME
662.44K
TURNOVER
18.08K
52 WEEK HIGH
2.760
52 WEEK LOW
0.015
MARKET CAP
1.67M
P/E (TTM)
-0.0133
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ATHX last week (1127-1201)?
Weekly Report · 2d ago
Weekly Report: what happened at ATHX last week (1120-1124)?
Weekly Report · 11/27 10:37
Weekly Report: what happened at ATHX last week (1113-1117)?
Weekly Report · 11/20 10:35
Athersys GAAP EPS of -$0.15
There was no revenue for the third quarter of 2023 compared with $0.1 million for the same period in 2022. Cash and cash equivalents were $1.0 million as of september 30, 2023. Athersys reported a q3 gaap eps of -$0.15.
Seeking Alpha · 11/17 11:28
Weekly Report: what happened at ATHX last week (1106-1110)?
Weekly Report · 11/13 10:30
Weekly Report: what happened at ATHX last week (1030-1103)?
Weekly Report · 11/06 10:34
Weekly Report: what happened at ATHX last week (1023-1027)?
Weekly Report · 10/30 10:46
Weekly Report: what happened at ATHX last week (1016-1020)?
Weekly Report · 10/23 10:38
More
About ATHX
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).

Webull offers Athersys Inc stock information, including OTCPK: ATHX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATHX stock methods without spending real money on the virtual paper trading platform.